TELUS Health Conference 2024: Exploring the link between mental health and financial security
Wellbeing has mental, physical and financial components, within the context of a social...
Insurers and benefits administrators
Event and Webinar
Article
TELUS Health Conference 2024: Reducing the impact of migraine in the workplace
For employees with migraine disease, workplace accommodations and quicker access to more effective,...
Event and Webinar
TELUS Health Annual Conference 2024: How AI is reshaping the benefits landscape
Generative artificial intelligence (AI) is a "transformative milestone" that will change our world...
Article
TELUS Health Annual Conference 2024: Drug trends and healthcare transformations
Diabetes, depression, attention deficit hyperactivity disorder (ADHD) and cystic fibrosis are among...
Event and Webinar
TELUS Health Annual Conference 2024
Presentations from April 23 and 30, 2024: Drug data trends and healthcare transformations Vicky...
Report
Get your copy: TELUS Health's 2024 Drug Data Trends & National Benchmarks report
For 16 years and counting, drugs for diabetes and depression have ranked in the top-five categories...
Report
What private plans need to know about Canada’s pipeline in 2024
In its 2024 Drug Pipeline report, TELUS Health draws attention to 12 new drugs due to their...
Article
Get to know the TELUS Health team: Mallory Coutu
Whether it’s from the TELUS office, the home office, or a TELUS Health medical clinic – our team...
Event and Webinar
Save the date: 20th TELUS Health Annual Conference
For two decades, TELUS Health has been at the forefront of healthcare innovation. As we gear up for...
Article
The road ahead for pharmacogenomic testing
Pharmacogenomic (PGx) testing may have the potential to revolutionize prescription drug use in...
Article
Revitalizing health connectivity through AI
In a groundbreaking collaboration, TELUS Health and Clinia have revealed an exclusive strategic...
Report
2023 Category Watch: A closer look at disruption
TELUS Health’s 2023 Category Watch closely examines disruption in the drug categories of diabetes,...
Article
Building a DE&I benefits tool kit
The workplaces of today are certainly diverse: they are a mix of employees with different racial...
Article
Arianne’s story: From cancer patient to preventive care advocate
“Something you never think about is how to tell your ten year old son you have cancer. It was the...
Article
Get to know the TELUS Health team: Dr. Matthew Chow
Whether it’s from the TELUS office, the home office, or a TELUS Health medical clinic – our team...
Article
Where coverage falls short plus other findings from the 2023 Benefits Canada Healthcare Survey
Half of plan members (51 per cent) reported that the coverage level of at least one of their health...
Article
Get to know the TELUS Health team: Paula Allen
Every day – whether it’s from the TELUS office, or the home office – our team members are...
Article
Getting value from private payor drug plans: Considering more than just costs
Following up on our Budget Impact Analysis (BIA) guidance document, TELUS Health has published...
Report
Your copy awaits: the 2023 Drug Data Trends & National Benchmarks report
At a high level, growth in spending by private drug plans was moderate for the third consecutive...
Article
TELUS Health conference 2023: Exploring the value of real-world evidence
At the TELUS Health Annual Conference on May 3, 2023, a panel of industry experts shared their...
Article
TELUS Health Conference: Understanding the mental health of tomorrow’s leaders
After three years of a global pandemic, the workplace has undergone a collective reset of mental...
Article
TELUS Health conference 2023: A deeper dive into drug utilization
Diabetes, asthma, depression and attention deficit hyperactivity disorder (ADHD)—these categories...
Article
TELUS Health conference 2023: What you need to know about drug data trends
The key drivers of change in spending by private drug plans in 2022 can be boiled down to two...
Article
TELUS Health Annual Conference 2023
Presentations from April 26 and May 3, 2023: Retrospective 2022: Drug data trends and national...
Article
How early mental health diagnoses can improve employees’ wellbeing
Many organizations have risen to the challenge when it comes to mental health. They understand the...
Article
A sneak peek at TELUS Health Annual Conference 2023
For the 19th consecutive year, TELUS Health is looking forward to welcoming a record number of...
Article
Everything that’s happening with biosimilars in Canada
The slow but steady adoption of biosimilars is big news. With provinces increasingly making the...
Article
How can pharmacogenetics help control employee benefit costs?
Pharmacogenetics (also known as pharmacogenomics) is one of the most exciting frontiers of medical...
Article
What private plans can expect in 2023 from Canada’s drug pipeline
Developments in the diabetes category—the second largest category by eligible amount in 2022—will...
Article
5 tools every plan sponsor should consider to cap benefits costs
The future of private drug insurance can be friendly – as long as plan sponsors take action in...
Article
Medication adherence: how to help employees stay on track and save your bottom line
How confident are you that your employees are taking the prescribed medications your plan pays for?...
Article
5 levers to slow the rise of pharmacy benefits costs
It’s no secret that drug costs are on the rise. In 2021, compared to 2020, plans saw a 5.0% rise in...
Article
Top 5 health benefits trends of 2023
If there’s any silver lining to the pandemic then it has to be the modernization of benefit plans...
Article
Mental health in the workplace - a prime focus for employers
Fostering a workplace where employees’ mental health is a priority is suddenly on everyone’s radar....
Article
It takes a village to improve mental health: How employers can contribute to employee well-being.
Supporting employee mental health and well-being is clearly the right thing to do – but it’s also a...
Article
What you need to know about drug data trends in 2022.
For the second year in a row, the pandemic has resulted in fewer plan members making claims for...
Event and Webinar
TELUS Health Annual Conference 2022
Presentations from May 10 & 17, 2022: Retrospective 2021: Data trends and national benchmarks.
Event and Webinar
From adherence to delayed diagnoses, what you need to know about medication use
Would it be better for patients to take more of a medication that may end up costing private drug...
Report
Don’t miss it: The 2022 Drug Data Trends & National Benchmarks report.
Year two of the COVID-19 pandemic saw the continuation of lower rates of prescribing for...
eBook
Working parents in crisis: How employers can better support parents in the workplace
This article was originally published in Benefits and Pensions Monitor. While parents in the...
eBook
From wellness to wellbeing: Why benefits plans need to evolve
Employers understand the need to invest in a healthy workforce, and employees increasingly look to...
Article
What’s your plan to help employees manage chronic conditions?
As Canada’s healthcare system strained and stretched to keep up with the shifting demands of the...
Report
2022 category watch: Impact of the pandemic
TELUS Health’s 2022 Category Watch examines the impact of the COVID-19 pandemic on drug utilization...
Article
Employers bracing for rising cancer claims
For the past two years, discussions around employee health have focused on mental wellness and...
Article
What new drugs are poised to have the biggest impact on plan costs?
The TELUS Health 2022 Drug Pipeline report looks at approved and likely soon-to-be-approved...
Article
Disability management post-COVID: What employers should know
Across the country, employers are working on their post-pandemic planning. In addition to setting...
Article
The private payer’s perspective: Drug trends
Panel discussion from the 20th Annual Market Access Summit. As the COVID-19 pandemic continues to...
Article
Drug plans decoded: Biosimilars Part 4
Biosimilars in Canada: what plan sponsors can do. For plan sponsors that want to take advantage of...
Article
Diabetes and Canadian employers
November is Diabetes Awareness Month in Canada. Like many chronic conditions, diabetes has taken a...
Article
Drug plans decoded: Biosimilars Part 3
Public plans drive adoption of biosimilars So far, four provinces in Canada —British Columbia,...
Article
Mental health, virtual care rise to surface: Highlights from the 2021 Benefits Canada Healthcare Survey
Employee health has declined over the past year, while the utilization of employee assistance...
Article
Can technology create great plan member experiences?
Managing group health benefits costs, digitizing benefits delivery and data insights are key areas...
Article
Supporting caregiver employees
The pandemic shone a bright light on the resilience of Canada’s healthcare system, and on the...
Article
Drug plans decoded: Biosimilars Part 2
How Canada compares on biosimilars. Canada lags many countries when it comes to the uptake of...
Article
Drug plans decoded: Biosimilars Part 1
Biosimilars 101: what you need to know. Four provinces so far have implemented or are implementing...
Event and Webinar
Canadian drug landscape update: Spring 2021 webinar
With new COVID treatments on the horizon, a growing number of biosimilar options available, and...
Report
Insights into the cost-effectiveness for cell and gene therapies
“Cell and gene therapies are some of the most exciting frontiers in modern medicine and have the...
Article
Humanizing the future of work
The past 15 months have seen a dizzying combination of accelerating, disrupted and new trends in...
Article
Estimating the financial impact of new medications for private drug plans
TELUS provides guidance on how to make a Budget Impact Analysis more relevant for private payers....
Article
2021 TELUS Health Drug Data Trends & National Benchmarks report
While COVID-19 clearly affected claims patterns for private drug plans in 2020, its net impact was,...
Article
British Columbia’s biosimilars policy a turning point for private plans
B.C.’s Biosimilars Initiative has had a profound impact on private drug plans. By the end of 2020,...
Article
Top 10 things plan sponsors need to know about depression
“There’s always a path ahead, no matter how severe your mental illness is,” said Chief Neuroscience...
Article
What you need to know about trends in medication use
The top three drug categories by eligible cost—for inflammatory disease, diabetes and skin...
Article
4 ways to prepare for the disability deluge
Within weeks of the coronavirus pandemic taking hold in Canada, plan sponsors, administrators and...
Event and Webinar
TELUS Health Annual Conference 2021
Presentations from April 20 & 27, 2021: Retrospective 2020: Data trends and national benchmarks
Event and Webinar
What to expect from Canada’s drug pipeline in 2021
Out of more than 150 drug submissions currently before Health Canada, the TELUS Health 2021 Drug...
Report
2021 category watch: The impact of new drugs
In its 2021 Category Watch: The Impact of New Drugs report, TELUS Health takes a closer look at the...
Article
Celebrating the women of TELUS Health Benefits Management
On this International Women’s Day, find out more about the roles these talented women on the Health...
Article
What plan sponsors can learn from The Globe and Mail’s Drug Shortages Summit
On February 17, 2021, The Globe and Mail hosted an online summit to explore the impact of drug...
Article
Mental health in organizations: How are people doing?
There’s no question it’s been a stressful year, full of challenges to mental health. So, what can...
Article
Are you prepared for the coming deluge of disability claims?
Despite some supply chain challenges, vaccination plans are coming together across Canada, and...
Article
Technology is set to transform mental health treatment
Can artificial intelligence (AI) provide accurate mental health diagnoses? Can virtual reality (VR)...
Article
Optimizing wellness programs with a data-driven approach
Employers provide wellness programs as an investment in their workforce. And a happy, healthy...
Article
Pharmacogenomic testing gains foothold in group insurance
Coverage of pharmacogenomic (PGx) testing is well underway in Canada. TELUS Health has contacted 10...
Article
Private payer perspective matters when considering drug cost-effectiveness
Incremental Cost-effectiveness ratios (ICERs) – which give payers an idea about the...
Article
The promise and potential of diabetes reversal
TELUS Health Annual Conference 2020 “Type 2 diabetes can be reversed.” Just a few years ago such a...
Article
Market access for biosimilars in Canada still below OECD average
TELUS Health Annual Conference – The rate of penetration of biosimilar drugs in the Canadian market...
Article
Getting down to the business of health
Plan sponsors are increasingly seeing the strong value equation that connects a healthy workforce...
Article
What private plans can expect from Canada’s drug pipeline
Canada may see its first gene therapy by the end of this year. The treatment is for a very rare eye...
Article
A closer look at the impact of breakthrough drugs in 5 categories
In the past five years, a number of drugs that represent significant advances in treatment for...
Article
Pharmacoeconomics: Evidence-informed drug reimbursement
A new drug may not seem affordable at face value, but is it cost-effective? Will it increase...